Wednesday Mar 5
Merck & Co., Inc.'s Investigational Hepatitis C Treatment Regimen...
Merck & Co., Inc. 's Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity In HIV/HCV Co-Infected Patients With HCV Genotype 1 Infection BOSTON, March 5, 2014 - Merck , known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY ... (more)
Trending on the Topix Network
Wednesday Mar 5
Merck & Co., Inc.'s Dust Mite Allergy Drug Reduces Symptoms In Phase 2b Study
Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet WHITEHOUSE STATION, N.J.-- -- Merck , known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual ... (more)
Mon Mar 03, 2014
GuruFocus Names Five Dividend Growers
During the past week, GuruFocus recognized five companies as dividend growers. In order to be qualified for this list, the company had to: The following five companies come from various industries and sectors of the market, but they all fit the necessary criteria needed to qualify them as dividend growers.
Fri Feb 28, 2014
Pensions & Investments
Merck to inject $250 million into pension funds this year
Merck & Co., Whitehouse Station, N.J., plans to contribute about $250 million to its defined benefit pension funds worldwide in 2014, according to its 10-K filed Thursday with the Securities and Exchange Commission.
Burlington Times News
PODCAST: Duke Energy, others haven't paid federal income tax since 2008
Some of North Carolina's most profitable corporations join a list of dozens of other Fortune 500 companies that pay little or no federal corporate income tax as a result of tax breaks and loopholes.
Wed Feb 26, 2014
BCC Research Publishes New Report On Global Market For Histone Deacetylase Inhibitors
According to a new technical market research report Histone Deacetylase Inhibitors: Emerging Markets, from BCC Research , the global market for histone deacetylase inhibitors was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013.
NYSE Active Stock Watch List: Merck & Co. Inc. (NYSE:MRK) and...
Equity Profile Report expands its NYSE Active Stock Weekly Watch List adding Merck & Co.
Tue Feb 25, 2014
New Report Available: Merck Sharp & Dohme Corp. (MRK) -...
Inc. Merck and Schering-Plough recently merged to create a new company. Merck & Co., Inc. is a research-driven pharmaceutical company established in 1891; Merck discovers, develops, manufactures and markets vaccines and medicines.
Fri Feb 21, 2014
Merck & Co., Inc. To Participate In The 2014 Healthcare Conference
Merck , known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, is scheduled to speak at the Citi 2014 Healthcare Conference in New York City on February 24, 2014 at 8:50 a.m. EST.
Tue Feb 18, 2014
A tale of two Mercks: a guide for confused protestors
Despite splintering into rival companies a century ago, Merck & Co. and Merck KGaA have once again been subject to mistaken identity, after protestors accidentally picketed the latter's London offices.
Iroko Pharmaceuticals Makes Strategic Additions to the Company's Board of Directors
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced the appointment of Bradley T. Sheares, Ph.D. and Louis Vollmer to the board of directors of Iroko Pharmaceuticals Inc. Dr. Sheares and Mr. Vollmer bring more than 50 years of combined pharmaceutical marketing ... (more)
Sun Feb 16, 2014
Merck: 7 Different Insiders Have Sold Shares This Month
In this article, I will feature one healthcare stock that has seen intensive insider selling during the last 30 days.
Sat Feb 15, 2014
Wall St. Cheat Sheet
Merck's Consumer Brands Portfolio Could Fetch Up to $10B
Merck & Co. Inc.'s plan to sell its portfolio of consumer brands is drawing a lot of attention.
Thu Feb 13, 2014
Bids For Merck & Co., Inc.'s Consumer Business Could Fetch $10 Billion
Merck & Co.' s effort to sell its portfolio of well-known consumer brands including Coppertone sun screen and Claritin allergy pills is kicking into high gear, with consumer and health care giants expected to put in bids that could top $10 billion, according to people familiar with the matter.
Tue Feb 11, 2014
The Papillion Times
Merck willing to settle suits over safety of contraceptive
Merck & Co. may pay $100 million to settle thousands of lawsuits over the safety of its NuvaRing contraceptive, a New Jersey judge held, as long as enough women agree to participate in the agreement.
The Washington Post
A Tale of Two Mercks as Protesters Take On Wrong Company: Health
Activists gathered with signs outside Merck's East London offices last week, protesting the drugmaker's involvement in a campaign to delay South Africa's proposal to allow low-cost copies of patented drugs.
Mon Feb 10, 2014
Merck and Samsung Bioepis Enter Collaboration Agreement to Develop...
Phase III clinical studies in type 1 and type 2 diabetes will begin soon. "We look forward to collaborating with Samsung Bioepis on this insulin glargine candidate, as diabetes is a top priority for the company," said Matt Strasburger, senior vice president, Diabetes, Global Human Health, Merck.